IRON down 56% Disc Medicine on Monday said a phase 2 study of its bitopertin drug candidate in patients with a rare, inherited metabolic disorder met its main goal but missed a key secondary target.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.